CI-980 in advanced melanoma and hormone refractory prostate cancer.

Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ
Invest New Drugs. 2000 18 (2): 187-91

PMID: 10857996 · DOI:10.1023/a:1006382014403

INTRODUCTION - CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines.

METHODS - 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks.

RESULTS - No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively.

CONCLUSIONS - CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

MeSH Terms (14)

Adult Aged Aged, 80 and over Antineoplastic Agents Carbamates Drug Resistance, Neoplasm Female Humans Male Melanoma Middle Aged Prostatic Neoplasms Pyrazines Pyridines

Connections (1)

This publication is referenced by other Labnodes entities: